Eli Lilly Q3 Profit Jumps 16% on Mounjaro, Zepbound; Raises FY26 Revenue Guidance

Eli Lilly (LLY) reported third-quarter net income of $6.45 billion, up 16% from $5.58 billion a year earlier, driven by strong sales of Mounjaro and Zepbound. The drugmaker raised its fiscal 2026 revenue outlook to $91 billion–$92 billion from a prior forecast of $85 billion–$87 billion, while trimming adjusted earnings guidance to $35.00–$36.00 per share from $35.50–$36.50. Revenue climbed 39% to $24.40 billion from $17.60 billion, reflecting a 53% volume increase partly offset by a 15% decline in realized prices. Mounjaro sales rose 65% to $10.72 billion, and Zepbound sales increased 49% to $5.35 billion. Adjusted EPS rose 7% to $7.48. Reported results included $4.57 per share in acquired in-process research and development charges tied to the AtaiBeckley and Curevo acquisitions, weighing on the adjusted earnings outlook. Lilly also raised its performance margin outlook to 52.0%–52.5% from 49.0%–50.5%. Shares rose 4.02% to $1,341 in pre-market trading Thursday.